Hjem › Immunforsvar og lidelser › New York › New York City
Kliniske studier for Immunforsvar og lidelser i New York City, NY
12 studier for Immunforsvar og lidelser søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Memorial Sloan Kettering Cancer Center, New York
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Memorial Sloan Kettering Cancer Center, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruttererFase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Abatacept for the Treatment of Giant Cell Arteritis
RekruttererFase 3
- Hospital for Special Surgery, New York
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RekruttererFase 2
- Inmagene Site 21, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruttererFase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RekruttererFase 2
- Columbia University Irving Medical Center, New York
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RekruttererFase 1/2
- Columbia University, New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruttererFase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Biologics And Clinical Immunology Cohort at Sinai
RekruttererObservasjonsstudie
- Mount Sinai, New York
Immunforsvar og lidelser-studier i andre byer
- Washington, DC13 studier
- Philadelphia, PA10 studier
- Boston, MA10 studier
- Atlanta, GA9 studier
- Portland, OR9 studier
- Houston, TX9 studier
- Los Angeles, CA8 studier
- Cleveland, OH8 studier
- Chicago, IL8 studier
- Milwaukee, WI6 studier
- Seattle, WA6 studier
- Cedar Rapids, IA6 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.